SRPT Sarepta Therapeutics Inc

Price (delayed)

$80.665

Market cap

$7.06B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.25

Enterprise value

$6.96B

Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going ...

Highlights
The EPS has soared by 52% YoY and by 17% from the previous quarter
The net income has increased by 49% YoY and by 15% QoQ
The company's equity has surged by 60% YoY but it fell by 8% QoQ
Sarepta Therapeutics's quick ratio has decreased by 5% YoY and by 3.8% from the previous quarter

Key stats

What are the main financial stats of SRPT
Market
Shares outstanding
87.5M
Market cap
$7.06B
Enterprise value
$6.96B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
8.2
Price to sales (P/S)
9.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.09
Earnings
Revenue
$765.79M
EBIT
-$355.7M
EBITDA
-$303.14M
Free cash flow
-$386.87M
Per share
EPS
-$4.25
Free cash flow per share
-$4.43
Book value per share
$9.83
Revenue per share
$8.78
TBVPS
$34.87
Balance sheet
Total assets
$3.06B
Total liabilities
$2.2B
Debt
$1.14B
Equity
$856.89M
Working capital
$2.08B
Liquidity
Debt to equity
1.33
Current ratio
5.56
Quick ratio
4.82
Net debt/EBITDA
0.32
Margins
EBITDA margin
-39.6%
Gross margin
86.1%
Net margin
-46.6%
Operating margin
-51.5%
Efficiency
Return on assets
-12.3%
Return on equity
-52.1%
Return on invested capital
-18.2%
Return on capital employed
-13.7%
Return on sales
-46.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SRPT stock price

How has the Sarepta Therapeutics stock price performed over time
Intraday
6.18%
1 week
7.61%
1 month
12.41%
1 year
12.05%
YTD
-10.42%
QTD
7.61%

Financial performance

How have Sarepta Therapeutics's revenue and profit performed over time
Revenue
$765.79M
Gross profit
$659.64M
Operating income
-$394.73M
Net income
-$356.56M
Gross margin
86.1%
Net margin
-46.6%
SRPT's net margin has surged by 62% year-on-year and by 22% since the previous quarter
SRPT's operating margin has soared by 51% YoY and by 21% from the previous quarter
The net income has increased by 49% YoY and by 15% QoQ
The revenue rose by 34% YoY and by 9% QoQ

Growth

What is Sarepta Therapeutics's growth rate over time

Valuation

What is Sarepta Therapeutics stock price valuation
P/E
N/A
P/B
8.2
P/S
9.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.09
The EPS has soared by 52% YoY and by 17% from the previous quarter
The company's equity has surged by 60% YoY but it fell by 8% QoQ
SRPT's P/B is 31% below its last 4 quarters average of 11.2 and 23% below its 5-year quarterly average of 10.0
The P/S is 60% less than the 5-year quarterly average of 21.8 and 16% less than the last 4 quarters average of 10.3
The revenue rose by 34% YoY and by 9% QoQ

Efficiency

How efficient is Sarepta Therapeutics business performance
The ROS has soared by 62% YoY and by 22% from the previous quarter
Sarepta Therapeutics's ROIC has soared by 51% YoY and by 20% from the previous quarter
The ROA has soared by 50% YoY and by 17% from the previous quarter
The return on equity is up by 40% year-on-year and by 25% since the previous quarter

Dividends

What is SRPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SRPT.

Financial health

How did Sarepta Therapeutics financials performed over time
The total assets is 39% more than the total liabilities
The total assets has increased by 11% YoY but it has decreased by 2.9% from the previous quarter
The company's current ratio fell by 11% YoY and by 3.3% QoQ
SRPT's debt is 33% greater than its equity
The company's equity has surged by 60% YoY but it fell by 8% QoQ
The debt to equity has declined by 38% year-on-year but it has increased by 8% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.